Analyst consensus implying roughly 83% price upside with a risk/reward ratio of nearly 11.8-to-1 reflects strong institutional conviction in this growth-stage biotech, but the business remains a substantial cash burner (free cash flow negative at 74% of revenue), concentrated in two products and a single supplier, and has missed earnings estimates in three of the last four quarters before a single recent beat.
Thesis pillars
- Exceptional Upside Risk Reward→Stable
- Elite Growth Metric Vs Cash Burn→Stable
- Momentum Recovery Not Yet Confirmed→Stable
- +1 more pillar — see the Why tab for full reasoning
Insmed Incorporated (INSM) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $111.69: Concentration risk — Product: ARIKAYCE and BRINSUPRI; Concentration risk — Supplier: Lamira device.
Insmed Incorporated commercializes two respiratory products—ARIKAYCE (approved US 2018, EU 2020, Japan 2021) for refractory MAC lung disease and BRINSUPRI (approved US August 2025, EU November 2025) for non-cystic fibrosis bronchiectasis. Revenue derives from prescription sales... Read more
Sell if holding. Multiple concerning factors at $111.69: Concentration risk — Product: ARIKAYCE and BRINSUPRI; Concentration risk — Supplier: Lamira device. Chart setup: Death cross but MACD improving, RSI 78. Score 5.1/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Insmed Incorporated
About Insmed Incorporated
BRINSUPRI (brensocatib) received FDA approval in August 2025 for non-cystic fibrosis bronchiectasis in patients 12 and older, followed by European Commission approval in November 2025; Insmed Incorporated's first commercial product, ARIKAYCE, received FDA accelerated approval in September 2018 for refractory MAC lung disease and is commercially approved in the US, EU, and Japan. Regulatory submissions for brensocatib in the UK and Japan have been accepted, with decisions anticipated in 2026. No other approved therapies for bronchiectasis exist in the US, Europe, or Japan as of the 10-K filing.
Insmed generates revenue from prescription sales of ARIKAYCE and BRINSUPRI in the US, EU, and Japan through its own sales force. ARIKAYCE is a drug/device combination requiring the Lamira nebulizer manufactured exclusively by PARI; the company cannot sell ARIKAYCE without Lamira, creating a single-source device dependency. Brensocatib was licensed from AstraZeneca in October 2016. The MAC lung disease addressable market spans the US, EU5, and Japan, while BRINSUPRI targets an estimated 500,000 bronchiectasis patients in the US, 600,000 in EU5, and 150,000 in Japan. The clinical pipeline includes TPIP (Phase 3 PALM-ILD study initiated Q4 2025 in PH-ILD; Phase 3 in PAH planned for H1 2026) and brensocatib for hidradenitis suppurativa (Phase 2b CEDAR study completed enrollment Q4 2025, topline data expected Q2 2026).
Show full overview
The confirmatory ENCORE trial—required by the FDA as a condition of ARIKAYCE's accelerated approval—enrolled 425 patients in Q4 2024 with topline data anticipated by April 2026. If ENCORE data are positive, Insmed plans to submit a supplementary NDA for ARIKAYCE in all MAC lung disease patients in H2 2026; if the trial fails, the FDA could withdraw accelerated approval under the Consolidated Appropriations Act, 2023. This binary readout, concurrent with BRINSUPRI's early commercial trajectory in bronchiectasis, makes 2026 a period of substantial clinical and regulatory uncertainty for the company.
See also: Healthcare · Biotechnology
From Insmed Incorporated's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-07-06Recent Developments — Insmed Incorporated
Latest news
- NEWS Analysts’ Opinions Are Mixed on These Healthcare Stocks: United Therapeutics (UTHR), Insmed (INSM) and MannKind (MNKD) - — The Globe and Mail neutral
- NEWS Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis - PR Newswire — PR Newswire positive
- NEWS Insmed (INSM) CEO sells 10,699 shares and exercises options under 10b5-1 plan - Stock Titan — Stock Titan negative
- NEWS INSM (Insmed Incorporated) Q4 2025 EPS misses consensus estimates, shares rise 5.07 percent on positive investor sentime — Newser negative
- NEWS What Insmed Incorporated (INSM) does that keeps customers coming back (-0.41%) 2026-05-05 - Insider Selling - Newser — Newser negative
Generated 2026-07-06T05:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductARIKAYCE and BRINSUPRI10-K Item 1A: 'Our prospects are highly dependent on the success of our approved products, ARIKAYCE and BRINSUPRI'
- HIGHSupplierLamira device10-K Item 1A: 'we cannot sell ARIKAYCE without Lamira'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $111.69: Concentration risk — Product: ARIKAYCE and BRINSUPRI; Concentration risk — Supplier: Lamira device. Chart setup: Death cross but MACD improving, RSI 78. Prior stop was $103.79. Score 5.1/10, moderate confidence.
Take-profit target: $177.34 (+58.9% upside). Prior stop was $103.79. Stop-loss: $103.79.
Concentration risk — Product: ARIKAYCE and BRINSUPRI; Concentration risk — Supplier: Lamira device; Leverage penalty (D/E 1.1): -0.5.
Insmed Incorporated trades at a P/E of N/A (forward 807.6). TrendMatrix value score: 3.0/10. Verdict: Sell.
29 analysts cover INSM with a consensus score of 4.3/5. Average price target: $197.
What does Insmed Incorporated do?Insmed Incorporated commercializes two respiratory products—ARIKAYCE (approved US 2018, EU 2020, Japan 2021) for...
Insmed Incorporated commercializes two respiratory products—ARIKAYCE (approved US 2018, EU 2020, Japan 2021) for refractory MAC lung disease and BRINSUPRI (approved US August 2025, EU November 2025) for non-cystic fibrosis bronchiectasis. Revenue derives from prescription sales in the US, EU, and Japan using the company's own sales force. The clinical pipeline includes TPIP in Phase 3 trials for PH-ILD and PAH, plus gene therapy programs.